OBJECTIVES: To evaluate the disease burden, it is essential to consider the patient's perspective on their health status, quality of life, and symptoms. These outcomes enable a comprehensive understanding of the disease and treatment impact on patients’ lives. We aim to describe the patient outcomes in a cohort treated at CUF, a private Hospitals’ network in Portugal.

METHODS: A cohort of patients with breast cancer seeking treatment has been under follow-up since 2016. All women with a new diagnosis of invasive breast cancer or ductal carcinoma in situ, undergoing any treatment are included. Patients with phyllodes tumors and recurrence at the time of program recruitment were excluded. The program collects electronic patient-reported outcomes measures (ePROMs) according to ICHOM standard sets which include EORTC QLQ-C30, EORTC QLQ-BR23, additional questions from BREASTQ and FACT-ES, through Promptly Collect platform at baseline, 6 months, and yearly to all patients.

RESULTS: A total of 856 patients were included until June 2024. The baseline score was 68.64 in EORTC QLQ-C30 with emotional functioning being the domain scoring lower (69.6) and insomnia and fatigue were the symptoms with higher impact (31.4 and 18.7 respectively). In EORTC QLQ-BR23, sexual pleasure, body image and hair loss were the domains with higher impact at baseline (73.3, 59.3 and 53.3 respectively). Throughout the follow-up period, the average scores varied across nearly all scales. In the EORTC QLQ-C30, the impact of symptoms like insomnia and fatigue were also among the highest among and also including pain and financial difficulties (24.18 and 24.18 at 6 year). In the EORTC QLQ-BR23, most of the dimensions had similar results with “Future Perspectives” being the one with the lowest results among all follow-up timings.

CONCLUSIONS: The results show variation in PROMS over time, highlighting the importance of continuous monitoring of quality of life and symptoms in breast cancer patients.